Growth Metrics

Galectin Therapeutics (GALT) Other Gross PP&E Adjustments (2011 - 2026)

Galectin Therapeutics' quarterly Other Gross PP&E Adjustments came in at -$67000.0 in Q1 2026, down 26.42% year-on-year from -$91051.3 in Q1 2025, and down 1216.67% quarter-over-quarter from $6000.0 in Q4 2025.

Galectin Therapeutics has reported Other Gross PP&E Adjustments for 16 years, with the latest figure at -$67000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Other Gross PP&E Adjustments fell 26.42% year-over-year to -$67000.0; the trailing twelve-month figure through Mar 2026 stood at -$285000.0 (up 4.36% YoY), and the FY2025 full-year result was $6000.0, changed N/A from the prior year.
  • Other Gross PP&E Adjustments for Q1 2026 stood at -$67000.0, down from $6000.0 in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $34000.0 in Q4 2023, with the low at -$150000.0 in Q3 2023.
  • Average Other Gross PP&E Adjustments over 5 years is -$74125.0, with a median of -$87000.0 recorded in 2022.
  • Peak annual rise in Other Gross PP&E Adjustments reached 277.78% in 2023, while the deepest fall reached 57.78% in 2023.
  • Tracing GALT's Other Gross PP&E Adjustments over 5 years: stood at $9000.0 in 2022, then surged by 277.78% to $34000.0 in 2023, then tumbled by 382.35% to -$96000.0 in 2024, then jumped by 106.25% to $6000.0 in 2025, then sank by 1216.67% to -$67000.0 in 2026.
  • The last three Other Gross PP&E Adjustments figures came in at -$67000.0 (Q1 2026), $6000.0 (Q4 2025), and -$94000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Gross PP&E Adjustments (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - -83,048.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -60,691.22
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -285.20 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -892,000.00
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -1.69 Bn
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -189.30 Mn
10 Galectin Therapeutics 165.77 Mn 151.67 Mn - -67,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -67,000.00
Mar 31, 2026 -67,000.00
Dec 31, 2025 6,000.00
Dec 31, 2025 6,000.00
Sep 30, 2025 -94,000.00
Sep 30, 2025 -94,000.00
Jun 30, 2025 -71,000.00
Jun 30, 2025 -71,000.00
Mar 31, 2025 -53,000.00
Mar 31, 2025 -53,000.00
Sep 30, 2024 -96,000.00
Sep 30, 2024 -96,000.00
Jun 30, 2024 -65,000.00
Jun 30, 2024 -65,000.00
Mar 31, 2024 -84,000.00
Mar 31, 2024 -84,000.00
Dec 31, 2023 34,000.00
Dec 31, 2023 34,000.00
Sep 30, 2023 -150,000.00
Sep 30, 2023 -150,000.00
Jun 30, 2023 -100,000.00
Jun 30, 2023 -100,000.00
Mar 31, 2023 -142,000.00
Mar 31, 2023 -142,000.00
Dec 31, 2022 9,000.00
Dec 31, 2022 9,000.00
Sep 30, 2022 -123,000.00
Sep 30, 2022 -123,000.00
Jun 30, 2022 -100,000.00
Jun 30, 2022 -100,000.00
Mar 31, 2022 -90,000.00
Mar 31, 2022 -90,000.00
Dec 31, 2021 6,000.00
Dec 31, 2021 6,000.00
Sep 30, 2021 -127,000.00
Sep 30, 2021 -127,000.00
Dec 31, 2020 -48,000.00
Dec 31, 2020 -48,000.00
Dec 31, 2019 74,000.00
Dec 31, 2019 74,000.00
Dec 31, 2018 74,000.00
Dec 31, 2018 74,000.00
Dec 31, 2017 74,000.00
Dec 31, 2017 74,000.00
Dec 31, 2016 74,000.00
Dec 31, 2016 74,000.00
Dec 31, 2015 74,000.00
Dec 31, 2015 74,000.00
Sep 30, 2015 -233,000.00
Sep 30, 2015 -233,000.00
Jun 30, 2015 -255,000.00
Jun 30, 2015 -255,000.00
Mar 31, 2015 -83,000.00
Mar 31, 2015 -83,000.00
Dec 31, 2014 -44,000.00
Dec 31, 2014 -44,000.00
Sep 30, 2014 -96,000.00
Sep 30, 2014 -96,000.00
Jun 30, 2014 -101,000.00
Jun 30, 2014 -101,000.00
Mar 31, 2014 -173,000.00
Mar 31, 2014 -173,000.00
Dec 31, 2013 -29,000.00
Dec 31, 2013 -29,000.00
Sep 30, 2013 -115,000.00
Sep 30, 2013 -115,000.00
Jun 30, 2013 -83,000.00
Jun 30, 2013 -83,000.00
Mar 31, 2013 -80,000.00
Mar 31, 2013 -80,000.00
Dec 31, 2012 -35,000.00
Dec 31, 2012 -35,000.00
Sep 30, 2012 -90,000.00
Sep 30, 2012 -90,000.00
Jun 30, 2012 -71,000.00
Jun 30, 2012 -71,000.00
Dec 31, 2011 252,000.00
Dec 31, 2011 252,000.00